WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Six months after President Donald Trump's foreign aid cuts, millions have lost access to HIV prevention medication.

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Global HIV leaders have urged African countries to fully own their HIV responses and called on governments to urgently invest in community-led systems to protect two decades of progress.ALSO READ: ...

The Joint United Nations Programme on HIV/AIDS (UNAIDS) warns that the global AIDS response is in crisis after a major funding collapse at the start of 2025 threatens to reverse decades of ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...

In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

The Trump administration has lifted a freeze on federal funds for HIV prevention and surveillance programs, officials said, following an outcry from HIV prevention organizations, health experts ...

Sub-Saharan Africa remains the epicenter of the AIDS pandemic. Trump's cuts have restricted the availability of drugs that millions of Africans have taken to prevent infection - particularly ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.